The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
2‐Methoxyestradiol, a Promising Anticancer Agent
Abstract
Estrogens occurring naturally in the body are metabolized to catecholestrogens (2‐ and 4‐hydroxyestradiol) by the cytochrome P450 enzymes. 2‐Hydroxy catecholestrogens are further metabolized by catechol‐ O ‐methyltransferase to 2‐methoxyestradiol, which is known to be protective against tumor formation. 2‐Methoxyestradiol exhibits potent apoptotic activity against rapidly growing tumor cells. It also possesses antiangiogenic activity through a direct apoptotic effect on endothelial cells. Other molecular mechanisms, including microtubule stabilization by inhibition of the colchicine‐binding site, have been reported. The exact mechanism of action of 2‐methoxyestradiol is still unclear, but it has been shown to be effective in preventing tumor growth in a variety of cell lines. 2‐Methoxyestradiol also possesses cardioprotective activity by inhibiting vascular smooth muscle cell growth in arteries. It has a lower binding affinity for estrogen receptor α compared with that of estradiol, and its affinity for estrogen receptor β is even lower than that of estrogen receptor α, thus it has minimal estrogenic activity. 2‐Methoxyestradiol is distinct because of its inability to engage estrogen receptors as an agonist, and its unique antiproliferative and apoptotic activities are mediated independently of estrogen receptors α and β. A phase I clinical trial of 2‐methoxyestradiol 200, 400, 600, 800, and 1000 mg/day in 15 patients with breast cancer showed significant reduction in bone pain and analgesic intake in some patients, with no significant adverse effects. Another phase I study of 2‐methoxyestradiol 200–1000 mg/day in combination with docetaxel 35 mg/m 2 /week for 4–6 weeks performed in 15 patients with advanced refractory metastatic breast cancer showed no serious drug‐related adverse effects. A phase II randomized, double‐blind trial of 2‐methoxyestradiol 400 and 1200 mg/day in 33 patients with hormone‐refractory prostate cancer showed that it was well tolerated and showed prostate specific antigen stabilizations and declines. We have started a phase I clinical trial to explore dosages greater than 1000 mg/day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Enzymatic O-methylation of epinephrine and other catechols
Axelrod, J., & Tomchick, R. (1958) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64731-3 · Cited by 1,283
Source of Estrogen Production in Postmenopausal Women1
GRODIN, J. M., SIITERI, P. K., & MACDONALD, P. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-36-2-207 · Cited by 959
Superoxide dismutase as a target for the selective killing of cancer cells
Huang, P., Feng, L., Oldham, E. A., Keating, M. J., & Plunkett, W. (2000) · Nature · doi:10.1038/35030140 · Cited by 842
Estrogen production and action
Nelson, L. R., & Bulun, S. E. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.117432 · Cited by 834
Fotsis, T., Zhang, Y., Pepper, M. S., Adlercreutz, H., Montesano, R., Nawroth, P. P., & Schweigerer, L. (1994) · Nature · doi:10.1038/368237a0 · Cited by 736
Nicosia, R. F., & Ottinetti, A. (1990) · PubMed · Cited by 597
Klauber, N., Parangi, S., Flynn, E. A., Hamel, E., & D’Amato, R. J. (1997) · PubMed · Cited by 524
Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice
Iafrati, M. D., Karas, R. H., Aronovitz, M., Kim, S., Sullivan, T. R., Lubahn, D. B., O'Donnell, T. F., Korach, K. S., & Mendelsohn, M. E. (1997) · Nature Medicine · doi:10.1038/nm0597-545 · Cited by 486
Cited by
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
Plottel, C. S., & Blaser, M. J. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.10.003 · Cited by 743
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., & Giannakakou, P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00077-1 · Cited by 730
Endogenous Inhibitors of Angiogenesis
Nyberg, P., Xie, L., & Kalluri, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2427 · Cited by 553
Understanding of ROS-Inducing Strategy in Anticancer Therapy
Kim, S. J., Kim, H. S., & Seo, Y. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5381692 · Cited by 406
Metadata
- Authors
- Lakhani, N. J., Sarkar, M. A., Venitz, J., & Figg, W. D.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2003-02
- Volume
- 23
- Issue
- 2
- Pages
- 165-172
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2139149338
- Cited by
- 274
- References
- 53
- FWCI
- 11.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2‐Methoxyestradiol, a Promising Anticancer Agent. https://app.cochat.ai/papers/10.1592/phco.23.2.165.32088
- The paper
- Lakhani, N. J., Sarkar, M. A., Venitz, J., & Figg, W. D. (2003). 2‐Methoxyestradiol, a Promising Anticancer Agent. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.23.2.165.32088
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.